Related Experiment Videos
[Laboratory and clinical studies cefroxadine in pediatric field (author's transl)]
Insights
Cefroxadine (CXD) is a new oral cephalosporin showing good activity against common bacteria. Clinical trials indicate it is effective for mild respiratory and urinary tract infections in children, with a high success rate and few side effects.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Background:
- Cefroxadine (CGP-9000, CXD) is an orally active cephalosporin developed by Ciba-Geigy.
- Evaluation of new antibiotics is crucial for combating bacterial infections.
Purpose of the Study:
- To assess the antibacterial activity, pharmacokinetics, and clinical efficacy of Cefroxadine (CXD).
- To determine the safety profile of CXD in pediatric patients.
Main Methods:
- Antibacterial activity was tested against clinically isolated organisms.
- Serum concentrations were measured in 6 patients after oral administration (10 mg/kg).
- Clinical efficacy was evaluated in 43 children with various infections, dosed at approximately 46 mg/kg daily.
Main Results:
- CXD demonstrated comparable activity to CEX against S. aureus and K. pneumoniae, and slightly stronger activity against E. coli.
- Peak serum levels of 11.66 mcg/ml were achieved 1 hour post-administration.
- An 88.4% effective rate was observed in 43 children, with excellent or good responses in most cases.
Conclusions:
- Cefroxadine (CXD) exhibits promising antibacterial properties and favorable pharmacokinetic profile.
- CXD appears effective and safe for treating mild respiratory and urinary tract infections in pediatric patients.
- Further investigation may be warranted for broader applications, but initial results suggest efficacy in less severe infections.
Abstract:
Cefroxadine (CGP-9000, CXD) is an orally active cephalosporin which has been newly developed by Ciba-Geigy. Its antibacterial activity against clinically isolated organisms, absorption and excretion after oral administration and clinical responses of patients with infections were studied. Its antibacterial activity against S. aureus and K. pneumoniae was comparable to that of CEX. Against E. coli, it showed slightly stronger activity than CEX. The serum concentrations of CXD was measured in 6 patients given orally 10 mg/kg of it after meals. The peak mean serum level attained 1 hour after administration was 11.66 mcg/ml. Forty-three children with various infections (upper respiratory infections, lower respiratory infections, urinary tract infections, etc.) were given 17 approximately 46 mg/kg (averaged 28.7 mg/kg) of CXD daily. The result was excellent in 26 cases, good in 12 cases, fair in 3 cases, fair in 3 cases and poor in 2 cases, showing an effective rate of 88.4%. Side effect of transient leukopenia and elevation of S-GOT were noticed in 2 cases. However, there were no serious adverse reactions in our study. It is concluded that CXD might be effective in rather mild cases of respiratory or urinary tract infections.